Home › Compare › MSNVF vs PFE

MSNVF vs PFE: Dividend Comparison 2026

MSNVF yields 222222.22% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSNVF wins by $1.4076447531278624e+30M in total portfolio value
10 years
MSNVF
MSNVF
● Live price
222222.22%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4076447531278624e+30M
Annual income
$1,406,399,782,569,334,400,000,000,000,000,000,000.00
Full MSNVF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — MSNVF vs PFE

📍 MSNVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSNVFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSNVF + PFE cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MSNVF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSNVF
Annual income on $10K today (after 15% tax)
$18,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, MSNVF beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSNVF + PFE for your $10,000?

MSNVF: 50%PFE: 50%
100% PFE50/50100% MSNVF
Portfolio after 10yr
$7.038223765639312e+29M
Annual income
$703,199,891,284,667,200,000,000,000,000,000,000.00/yr
Blended yield
99.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MSNVF
No analyst data
Altman Z
-46.6
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSNVF buys
0
PFE buys
0
No recent congressional trades found for MSNVF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSNVFPFE
Forward yield222222.22% ✓6.20%
Annual dividend / share$2.00 ✓$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2% ✓
Portfolio after 10y$1.4076447531278624e+30M$51.1K ✓
Annual income after 10y$1,406,399,782,569,334,400,000,000,000,000,000,000.00 ✓$27,210.54
Total dividends collected$1.4075632434891558e+30M$60.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSNVF vs PFE ($10,000, DRIP)

YearMSNVF PortfolioMSNVF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$22,232,922$22,222,222.22$9,161$701.38+$22.22M → MSNVF
2$46,198,082,523$46,174,293,296.41$8,610$859.79+$46198.07M → MSNVF
3$89,718,752,943,223$89,669,320,994,923.30$8,366$1,081.25+$89718752.93M → MSNVF
4$162,845,393,609,755,680$162,749,394,544,106,430.00$8,483$1,405.66+$162845393609.75M → MSNVF
5$276,249,735,879,778,500,000$276,075,491,308,616,120,000.00$9,084$1,907.24+$276249735879778.50M → MSNVF
6$437,989,462,258,048,500,000,000$437,693,875,040,657,100,000,000.00$10,418$2,732.78+$437989462258048512.00M → MSNVF
7$649,026,142,700,674,900,000,000,000$648,557,493,976,058,700,000,000,000.00$13,007$4,193.56+$649026142700674875392.00M → MSNVF
8$898,874,153,179,794,200,000,000,000,000$898,179,695,207,104,400,000,000,000,000.00$18,010$7,005.87+$8.988741531797941e+23M → MSNVF
9$1,163,523,886,474,633,300,000,000,000,000,000$1,162,562,091,130,731,000,000,000,000,000,000.00$28,216$12,979.89+$1.1635238864746333e+27M → MSNVF
10$1,407,644,753,127,862,300,000,000,000,000,000,000$1,406,399,782,569,334,400,000,000,000,000,000,000.00$51,081$27,210.54+$1.4076447531278624e+30M → MSNVF

MSNVF vs PFE: Complete Analysis 2026

MSNVF — Stock

Mission Ready Solutions Inc. provides personal protective solutions to the global defense, security, and first-responder markets in Canada and the United States. the company operates through two segments Consulting and Manufacturer Representation; and Inspection, Cleaning, and Repair Services. It offers protective services gears. The company also distributes, fire, military, emergency, and law enforcement products. It serves the Department of Defense, law enforcement agencies, and private security companies. The company was formerly known as Mission Ready Services Inc. and changed its name to Mission Ready Solutions Inc. in June 2018. Mission Ready Solutions Inc. is headquartered in Vancouver, Canada.

Full MSNVF Calculator →

PFE — Healthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MSNVF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSNVF vs SCHDMSNVF vs JEPIMSNVF vs OMSNVF vs KOMSNVF vs MAINMSNVF vs JNJMSNVF vs MRKMSNVF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.